Fate Therapeutics Licenses Stem-Cell Modulators for Bone Regeneration from UCLA

UCLA becomes at least the eighth university or research institution from which Fate licensed IP to bolster its portfolio of stem cell modulators — small molecules and biologics to modulate cells for therapeutic purposes.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories